A Novel Multiplex ELISA Assay for Evaluating Patients With Microscopic Hematuria for Bladder Cancer
Trial Summary
What is the purpose of this trial?
To improve upon the non-invasive detection of BCa by further validating a multiplex ELISA assay directed at a BCa-associated diagnostic signature in voided urine samples of patients with microscopic hematuria.
Research Team
Hideki Furuya, PhD
Principal Investigator
Cedars-Sinai Medical Center
Charles Rosser, MD
Principal Investigator
Nonagen Bioscience Corporation
Eligibility Criteria
Inclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Diagnostic Evaluation
Participants undergo a non-invasive multiplex ELISA assay to detect BCa-associated diagnostic signatures in voided urine samples
Follow-up
Participants are monitored for safety and effectiveness after the diagnostic evaluation
Treatment Details
Interventions
- A Novel Multiplex ELISA Assay
Find a Clinic Near You
Who Is Running the Clinical Trial?
Cedars-Sinai Medical Center
Lead Sponsor
Charles Rosser
Lead Sponsor
University of Texas, Southwestern Medical Center at Dallas
Collaborator
Nara Prefecture Seiwa Medical Center
Collaborator
VA Long Beach Healthcare System
Collaborator
National Cancer Institute (NCI)
Collaborator
Nara Medical University
Collaborator
Nonagen Bioscience Corporation
Industry Sponsor
University of California, Los Angeles
Collaborator
University of Rochester
Collaborator